The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

The company's shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...